The application of patient-reported outcomes in clinical trials of digestive tract tumors conducted in China: a cross-sectional study of registered clinical trial protocols

Abstract

Introduction With the adoption of international health standards, patient-reported outcomes (PROs) are increasingly used in clinical trials, promoting the effective implementation of patient-centered healthcare. However, the characteristics of PRO use in digestive tract tumor trials in China remain poorly understood. The aim of this study was to evaluate PRO application and characteristics in randomized clinical trials of digestive tract tumors conducted in China. Methods In this cross-sectional study, we identified data from the ClinicalTrials.gov database and the Chinese Clinical Trial Registry and the dataset was restricted to randomized clinical trials of digestive tract tumors conducted in China between January 1, 2010, and June 30, 2025. Trials were classified into four groups: (1) those listing PROs as primary outcomes; (2) those listing PROs as secondary outcomes; (3) trials listing PROs as co-primary outcomes (both primary and secondary); and (4) trials without any PRO instrument. Results Of 2292 trials, 928 (40.5%) incorporated PRO instruments as part of their results. Among these, 29.6% (275/928) listed PRO as primary outcomes, 54.2% (503/928) as secondary outcomes, and 16.2% (150/928) as co-primary outcomes. The most frequent conditions for the explicit use of specific PRO instruments included colorectal (405/928, 43.6%), stomach (229/928, 24.7%), and esophageal (166/928, 17.9%) tumors. Commonly used PRO instruments included the Visual Analog Scale, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, and the Numeric Rating scale. Among relevant trials, only 4.8% (6/125) used the traditional Chinese medicine (TCM) Symptom Score. Conclusions Recently, PRO use has shown an increasing trend in randomized clinical trials on digestive tract tumors conducted in China. Nonetheless, the low proportion of clinical trials of digestive tract tumors using PROs remains noteworthy. Future efforts should develop TCM-specific PRO tools and integrate TCM syndrome scales with Western PROs in TCM-oncology trials.

Keywords

patient-reported outcome / digestive tract tumor / cross-sectional study / quality-of-life

References

[1] Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007; 10(Suppl 2):S125-S137.

[2] Carrozzino D, Patierno C, Guidi J, et al. Clinimetric criteria for patient-reported outcome measures. Psychother Psychosom. 2021; 90(4):222-232.

[3] Casey DE Jr. Patient-reported outcome measures-challenges and opportunities for China. JAMA Netw Open. 2022; 5(5):e2211652.

[4] Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013; 346(jan28 1):f167.

[5] McGee RG. How to include patient-reported outcome measures in clinical trials. Curr Osteoporos Rep. 2020; 18(5):480-485.

[6] Zhou H, Yao M, Gu X, et al. Application of patient-reported outcome measurements in clinical trials in China. JAMA Netw Open. 2022; 5(5):e2211644.

[7] Basch E, Dueck AC, Mitchell SA, et al. Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (alliance N1048). J Clin Oncol. 2023; 41(21):3724-3734.

[8] Brenkman HJF, Tegels JJW, Ruurda JP, et al. Factors influencing health-related quality of life after gastrectomy for cancer. Gastric Cancer. 2018; 21(3):524-532.

[9] Harrison NJ, Lopez AA, Shroder MM, et al. Collection and utilization of patient-reported outcome measures in a colorectal surgery clinic. J Surg Res. 2022; 280:515-525.

[10] Noonan VK, Lyddiatt A, Ware P, et al. Montreal accord on patient-reported outcomes (PROs) use series - Paper 3: patient-reported outcomes can facilitate shared decision-making and guide self-management. J Clin Epidemiol. 2017; 89:125-135.

[11] Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007; 57(5):278-300.

[12] Straatman J, van der Wielen N, Joosten PJ, et al. Assessment of patient-reported outcome measures in the surgical treatment of patients with gastric cancer. Surg Endosc. 2016; 30(5):1920-1929.

[13] Karanicolas PJ, Bickenbach K, Jayaraman S, et al. Measurement and interpretation of patient-reported outcomes in surgery: an opportunity for improvement. J Gastrointest Surg. 2011; 15(4):682-689.

[14] Dong Y, Liu L, Zhang X, et al. A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China. Front Pharmacol. 2023; 14:1159906.

[15] Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76(2):182-188.

[16] DeRenzo EG, Moss J, Singer EA. Implications of the revised common rule for human participant research. Chest. 2019; 155(2):272-278.

[17] Cuschieri S.The STROBE guidelines. Saudi J Anaesth. 2019; 13(5):31.

[18] Gnanasakthy A, Russo J, Gnanasakthy K, Harris N, Castro C. A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp Clin Trials. 2022; 120:106860.

[19] Nielsen AS, Kidholm K, Kayser L. Patients’ reasons for non-use of digital patient-reported outcome concepts: a scoping review. Health Informatics J. 2020; 26(4):2811-2833.

[20] Cooper L, Wo E, Lee I. A 15 year review (2006-2020) of patient-reported outcome (PRO) in United States oncology product labeling and trends in sponsor size and oncology experience. Arch Intern Med Res. 2022; 5(3):412-419.

[21] Calvert M, Kyte D, Duffy H, et al. Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS One. 2014; 9(10):e110216.

[22] Nguyen H, Butow P, Dhillon H, Sundaresan P. A review of the barriers to using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine cancer care. J Med Radiat Sci. 2021; 68(2):186-195.

[23] Fiteni F, Cuenant A, Favier M, Cousin C, Houede N. Clinical relevance of routine monitoring of patient-reported outcomes versus clinician-reported outcomes in oncology. In Vivo. 2019; 33(1):17-21.

[24] Schwartz CE, Finkelstein JA, Rapkin BD. Appraisal assessment in patient-reported outcome research: methods for uncovering the personal context and meaning of quality of life. Qual Life Res. 2017; 26(3):545-554.

[25] Ciani O, Meregaglia M, Battaglia MA, et al. Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022. Neurol Sci. 2023; 44(8):2933-2937.

[26] Basch E, Dueck AC. Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data. Expert Opin Drug Discov. 2016; 11(8):753-758.

[27] Dougados M, Nataf H, Steinberg G, Rouanet S, Falissard B. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology. 2013; 52(2):391-399.

[28] Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019; 20(2):273-286.

[29] Liniker E, Harrison M, Weaver JMJ, et al. Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010). Br J Cancer. 2013; 109(8):2051-2057.

[30] Atkinson TM, Stover AM, Storfer DF, et al. Patient-reported physical function measures in cancer clinical trials. Epidemiol Rev. 2017; 39(1):59-70.

[31] Sun L, Wang F, Wang X, Zhang F, Ma S, Lyu J. SATB1 mediated tumor colonization and β-catenin nuclear localization are associated with colorectal cancer progression. Cancer Biol Ther. 2024; 25(1):2320307.

[32] Soerjomataram I, Thong MSY, Ezzati M, Lamont EB, Nusselder WJ, van de Poll-Franse LV. Most colorectal cancer survivors live a large proportion of their remaining life in good health. Cancer Causes Control. 2012; 23(9):1421-1428.

[33] Hsu T, Speers CH, Kennecke HF, Cheung WY. The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer. Cancer. 2017; 123(10):1839-1847.

[34] Bottomley A, Pe M, Sloan J, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016; 17(11):e510-e514.

[35] Rivera SC, Kyte DG, Aiyegbusi OL, Slade AL, McMullan C, Calvert MJ. The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis. Health Qual Life Outcomes. 2019; 17(1):156.

[36] Crites JS, Chuang C, Dimmock A, et al. PROs in the balance: ethical implications of collecting patient reported outcome measures in the electronic health record. Am J Bioeth. 2016; 16(4):67-68.

[37] Ganesh V, Agarwal A, Popovic M, et al. Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Support Care Cancer. 2016; 24(8):3661-3668.

[38] Homs MYV, Kuipers EJ, Siersema PD. Palliative therapy. J Surg Oncol. 2005; 92(3):246-256.

[39] McDonald JJ, Fallon MT, Laird BJA. Meaningful measures in cancer cachexia: implications for practice and research. Curr Opin Support Palliat Care. 2019; 13(4):323-327.

[40] Karcioglu O, Topacoglu H, Dikme O, Dikme O. A systematic review of the pain scales in adults: Which to use? Am J Emerg Med. 2018; 36(4):707-714.

[41] Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011; 41(6):1073-1093.

[42] Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res. 2011; 63(Suppl 11):S240-S252.

[43] Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005; 14(7):798-804.

[44] Woo A, Fu T, Popovic M, et al. Comparison of the EORTC STO-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer. Ann Palliat Med. 2016; 5(1):13-21.

[45] Straatman J, Joosten PJM, Terwee CB, Cuesta MA, Jansma EP, van der Peet DL. Systematic review of patient-reported outcome measures in the surgical treatment of patients with esophageal cancer. Dis Esophagus. 2016; 29(7):760-772.

[46] Cella D, Gershon R, Lai JS, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res. 2007; 16(Suppl 1):133-141.

[47] Li Y, Jing D, Xiao Y, Huang X, Shen M. Patient-reported outcomes of arsenic-related skin lesions in China. Biomed Res Int. 2020; 2020:6195975.

[48] Liu N, Lv J, Liu J, Zhang Y. The PU-PROM: a patient-reported outcome measure for peptic ulcer disease. Health Expect. 2017; 20(6):1350-1366.

[49] Tang L, Zhang Y, Pang Y. Patient-reported outcomes from the distress assessment and response tool program in Chinese cancer inpatients. Psychooncology. 2020; 29(5):869-877.

[50] Howell D, Fitch M, Bakker D, et al. Core domains for a person-focused outcome measurement system in cancer (PROMS-Cancer Core) for routine care: a scoping review and Canadian Delphi Consensus. Value Health. 2013; 16(1):76-87.

[51] Ni M, Zhang Y, Sun Z, et al. Efficacy and safety of Shenbai Granules for recurrent colorectal adenoma: a multicenter randomized controlled trial. Phytomedicine. 2024; 127:155496.